ATE187062T1 - Formulierungen zum suspendieren: von proteine und peptiden - Google Patents

Formulierungen zum suspendieren: von proteine und peptiden

Info

Publication number
ATE187062T1
ATE187062T1 AT96920358T AT96920358T ATE187062T1 AT E187062 T1 ATE187062 T1 AT E187062T1 AT 96920358 T AT96920358 T AT 96920358T AT 96920358 T AT96920358 T AT 96920358T AT E187062 T1 ATE187062 T1 AT E187062T1
Authority
AT
Austria
Prior art keywords
peptides
proteins
beneficial agent
suspension formulations
suspension
Prior art date
Application number
AT96920358T
Other languages
English (en)
Inventor
James B Eckenhoff
Leslie A Holladay
John Joseph Leonard Jr
Iris K M Leung
Sally A Tao
Judy A Magruder
John P Carr
Jeremy Wright
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE187062T1 publication Critical patent/ATE187062T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT96920358T 1995-06-07 1996-05-22 Formulierungen zum suspendieren: von proteine und peptiden ATE187062T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/475,238 US5904935A (en) 1995-06-07 1995-06-07 Peptide/protein suspending formulations

Publications (1)

Publication Number Publication Date
ATE187062T1 true ATE187062T1 (de) 1999-12-15

Family

ID=23886776

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96920358T ATE187062T1 (de) 1995-06-07 1996-05-22 Formulierungen zum suspendieren: von proteine und peptiden

Country Status (14)

Country Link
US (2) US5904935A (de)
EP (1) EP0831773B1 (de)
JP (2) JPH11506730A (de)
KR (1) KR100460653B1 (de)
CN (1) CN1138528C (de)
AT (1) ATE187062T1 (de)
AU (1) AU706318B2 (de)
CA (1) CA2220871C (de)
DE (1) DE69605417T2 (de)
DK (1) DK0831773T3 (de)
ES (1) ES2139360T3 (de)
FI (1) FI119464B (de)
NZ (1) NZ308843A (de)
WO (1) WO1996040049A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
CZ286632B6 (cs) 1992-09-29 2000-05-17 Inhale Therapeutic Systems Farmaceutický prostředek
EP1462096B1 (de) 1994-03-07 2008-12-10 Nektar Therapeutics Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
WO1999055310A1 (en) 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
HK1038508B (en) * 1998-09-09 2006-06-30 Alza Corporation Dosage form comprising liquid formulation
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
CA2361424C (en) * 1999-02-08 2009-04-28 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
KR20080011353A (ko) 2000-02-24 2008-02-01 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
US6992065B2 (en) 2000-04-19 2006-01-31 Genentech, Inc. Sustained release formulations
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
MXPA03000073A (es) * 2000-06-26 2003-09-25 Monsanto Technology Llc Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina.
US6664234B1 (en) * 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US20020114843A1 (en) 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
NZ526720A (en) * 2000-12-28 2007-11-30 Altus Pharmaceuticals Inc Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
AU2002242231B2 (en) * 2001-02-23 2007-09-06 Genentech, Inc. Erodible polymers for injection
CA2448218C (en) * 2001-06-21 2012-05-29 Genentech, Inc. Sustained release formulation
CA2451185A1 (en) * 2001-06-21 2003-01-03 Altus Biologics, Inc. Spherical protein particles and methods of making and using them
WO2003053411A1 (en) 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
NZ537136A (en) * 2002-06-17 2007-07-27 Alza Corp Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle
CA2508124A1 (en) * 2002-12-19 2004-07-08 Alza Corporation Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2520766A1 (en) * 2003-03-31 2004-10-21 Alza Corporation Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
DE602004012081T2 (de) * 2003-03-31 2009-03-19 Intarcia Therapeutics, Inc., Emeryville Osmotische pumpe mit mitteln zum ableiten des innendrucks
CA2530136C (en) 2003-06-26 2012-10-16 Control Delivery Systems, Inc. In-situ gelling drug delivery system
CA2530113C (en) 2003-06-26 2013-08-13 Control Delivery Systems, Inc. Bioerodible sustained release drug delivery systems
US7459021B2 (en) 2003-09-03 2008-12-02 Shmuel Bukshpan Methods and apparatus for rapid crystallization of biomolecules
MXPA06002030A (es) * 2003-10-31 2006-05-17 Alza Corp Bomba osmotica con tapon de membrana de auto-retencion, de rapido inicio.
JP2007526792A (ja) * 2003-11-06 2007-09-20 アルザ・コーポレーシヨン 移植可能な浸透ポンプと一緒の使用のためのモジュール型の吸入速度低下器
KR101040415B1 (ko) 2004-04-15 2011-06-09 알케르메스,인코포레이티드 중합체 기재 지속적 방출 방법
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060029551A1 (en) * 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
US20060045891A1 (en) * 2004-08-24 2006-03-02 Lovalenti Phillip M Density-matched suspension vehicles and pharmaceutical suspensions
US7655254B2 (en) * 2005-02-03 2010-02-02 Intarcia Therapeutics, Inc. Implantable device for continuous delivery of interferon
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US7759312B2 (en) 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
EP2457564A1 (de) * 2005-03-11 2012-05-30 Endo Pharmaceuticals Solutions Inc. Octreotid-Formulierungen mit kontrollierter Freisetzung
US7959938B2 (en) 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
AU2007266475B2 (en) 2006-05-30 2009-12-03 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
JP5048773B2 (ja) * 2006-08-09 2012-10-17 インターシア セラピューティクス，インコーポレイティド 浸透圧式デリバリーシステム及びピストンアセンブリー
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
RU2463079C2 (ru) 2007-04-27 2012-10-10 Эндо Фармасьютикалз Солюшнз Инк. Разделительные агенты для имплантируемого устройства и способы их применения
CN101674812B (zh) * 2007-04-30 2013-12-11 诺沃-诺迪斯克有限公司 干燥蛋白组合物的方法、干燥的蛋白组合物和包含干燥的蛋白的药物组合物
DK2170283T3 (en) 2007-06-22 2019-04-15 Univ Texas CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
WO2009158412A2 (en) 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
EP2317975B1 (de) 2008-06-25 2016-04-13 Endo Pharmaceuticals Solutions Inc. Octreotid-implantat mit freisetzungsmittel
KR20170138580A (ko) 2008-08-15 2017-12-15 아이언우드 파마슈티컬스, 인코포레이티드 경구 투여를 위한 리나클로타이드-함유 제형
AU2009303905B2 (en) * 2008-10-15 2015-01-22 Intarcia Therapeutics, Inc. Highly concentrated drug particles, formulations, suspensions and uses thereof
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
EP3466438A1 (de) 2009-08-03 2019-04-10 Incube Labs, Llc Schluckbare kapsel und verfahren zur stimulation der inkretinproduktion innerhalb des darmtrakts
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US8562589B2 (en) 2009-12-24 2013-10-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
UA108636C2 (xx) 2010-02-17 2015-05-25 Пептид
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
LT2603232T (lt) 2010-08-11 2020-01-27 Ironwood Pharmaceuticals, Inc. Stabilios linaklotido vaisto formos
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809271B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9149617B2 (en) 2010-12-23 2015-10-06 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8764733B2 (en) 2010-12-23 2014-07-01 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
ES2614864T3 (es) 2011-08-17 2017-06-02 Ironwood Pharmaceuticals, Inc. Tratamientos para trastornos gastrointestinales
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732865A (en) * 1971-01-13 1973-05-15 Alza Corp Osmotic dispenser
US3833725A (en) * 1972-12-08 1974-09-03 Syntex Corp Dialkylated glycol compositions and medicament preparations containing same
US4036954A (en) * 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
US4180560A (en) * 1976-10-26 1979-12-25 Syntex Corporation Inert core implant pellet
US4215691A (en) * 1978-10-11 1980-08-05 Alza Corporation Vaginal contraceptive system made from block copolymer
US4237885A (en) * 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
US4389414A (en) * 1981-05-11 1983-06-21 Syntex (U.S.A.) Inc. Prostaglandin compositions
US4507281A (en) * 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
US4475916A (en) * 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4483849A (en) * 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
JPS60501759A (ja) * 1983-07-01 1985-10-17 バテル　メモリアル　インステイチユ−ト 生物分解性ポリペプチド及び薬剤の緩慢な放出のためのその使用
US4855134A (en) * 1983-10-14 1989-08-08 Sumitomo Pharmaceuticals Company, Limited Sustained-release preparation
GB2155889B (en) * 1984-03-21 1988-03-02 Alza Corp Dispenser-capsule
US5032572A (en) * 1984-07-18 1991-07-16 Medical College Of Ohio Polymers containing cross-linked azo bonds, which polymers are useful for releasing therapeutic agents into the lower gastrointestinal tract
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
JPS63281299A (ja) * 1987-05-13 1988-11-17 Hitachi Ltd 連想メモリ装置
EP0294160A1 (de) * 1987-06-02 1988-12-07 Schering Corporation Behandlung von chronischer Hepatitis B mit einer Mischung menschlicher rekombinanter Alpha- und Gamma-Interferone
US4871538A (en) * 1987-07-13 1989-10-03 Schering Corporation Insoluble copper-alpha interferon complex
IT1222734B (it) * 1987-09-25 1990-09-12 Scalvo S P A Formulaziopne farmaceutiche e forme di dosaggio per la somminaistarzione rettale di calcitonina
US4855141A (en) * 1988-03-25 1989-08-08 Alza Corporation Device comprising means for protecting and dispensing fluid sensitive medicament
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
EP0374120A3 (de) * 1988-12-13 1991-07-31 Monsanto Company Zusammensetzung mit kontrollierter Wirkstoffabgabe von Polypeptiden
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
JP2514249B2 (ja) * 1989-05-23 1996-07-10 帝人株式会社 安定化されたカルシトニン類医薬組成物
US5100392A (en) * 1989-12-08 1992-03-31 Biosynthesis, Inc. Implantable device for administration of drugs or other liquid solutions
IT1242642B (it) * 1990-04-17 1994-05-16 Alfa Wassermann Spa Formulazioni iniettabili contenenti naproxen sale sodico.
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5236707A (en) * 1991-11-08 1993-08-17 Dallas Biotherapeutics, Inc. Stabilization of human interferon
JP3730667B2 (ja) * 1991-12-27 2006-01-05 武田薬品工業株式会社 注射用組成物
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5221278A (en) * 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
WO1995010989A1 (en) * 1993-10-19 1995-04-27 Scimed Life Systems, Inc. Intravascular stent pump
DK0768867T3 (da) * 1994-06-13 2002-10-28 Alza Corp Doseringsform til indgivelse af lægemiddel i væskeformig formulering
WO1999008832A1 (de) * 1997-08-20 1999-02-25 Mikron Sa Agno Vorrichtung zum bewegen und positionieren eines gegenstandes in einer ebene

Also Published As

Publication number Publication date
CA2220871C (en) 2011-02-08
EP0831773B1 (de) 1999-12-01
FI119464B (fi) 2008-11-28
US5972370A (en) 1999-10-26
KR19990022486A (ko) 1999-03-25
CN1138528C (zh) 2004-02-18
JP2009057389A (ja) 2009-03-19
WO1996040049A1 (en) 1996-12-19
CN1187119A (zh) 1998-07-08
DE69605417T2 (de) 2000-03-23
DK0831773T3 (da) 2000-05-08
ES2139360T3 (es) 2000-02-01
CA2220871A1 (en) 1996-12-19
AU5869496A (en) 1996-12-30
AU706318B2 (en) 1999-06-17
FI974429A0 (fi) 1997-12-05
FI974429L (fi) 1997-12-05
KR100460653B1 (ko) 2005-08-05
NZ308843A (en) 2000-01-28
EP0831773A1 (de) 1998-04-01
US5904935A (en) 1999-05-18
JPH11506730A (ja) 1999-06-15
DE69605417D1 (de) 2000-01-05

Similar Documents

Publication Publication Date Title
ATE187062T1 (de) Formulierungen zum suspendieren: von proteine und peptiden
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
DE69430635D1 (de) Loteprednoletabonat-suspension
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
IL109403A0 (en) Oral drug delivery compositions and methods
IL113812A0 (en) Copolymer-1, pharmaceutical compositions containing it and its use
MX9700223A (es) Composicion farmaceutica para la liberacion controlada de moguisteina en una suspension liquida.
DE69522343D1 (de) Gelstiftzusammensetzung enthaltend gebildner angereichert in optisch aktiver form
MX9801732A (es) Anticuerpos anti-cd4 recombinantes para la terapia a humanos.
GEP19981289B (en) Method for Preparing Preserved Medicinal Means Containing Human Protein and Medicinal Means
IL172835A0 (en) A composition for stabilizing active protein ingredients in pharmaceutical composition containing at least 2 amino acids
DE69433723D1 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
PT749317E (pt) Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
DE69324006D1 (de) Zubereitungen von hyaluronsaeure mit niedrigem molekulargewicht zur foerderung der knochenbildung
BG104057A (en) Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutical application
IL98917A0 (en) Piperidyl ethers and thioethers and their use as inhibitors of cholesterol biosynthesis
BE1014502A5 (fr) Compositions pharmaceutiques.
TR200000291T2 (tr) Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
DE69524971D1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
MX9709907A (es) Formulaciones de suspension de peptido/proteina.
FR2768145B1 (fr) Nouveaux composes derives d'acide alkylene diamine di- ou tri-acetique, leur procede de preparation, leur utilisation dans des compositions cosmetiques et pharmaceutiques, et compositions les comprenant
SE8500102L (sv) Forfarande for mikrofloraavlossning
EP0817643A4 (de) Stoffe und zusammensetzungen für die verabreichung aktiver substanzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties